Who Are the Core Customers in Science Group Company's Target Market?

R&D directors and product heads at global pharmaceutical and medtech firms drive the largest contracts, seeking integrated discovery-to-clinic solutions; these clients accounted for roughly 45% of Science Group plc's 2025 revenues in professional scientific services.

Regulatory heads in chemical and food & beverage firms plus government defense agencies and industrial manufacturers buy complex compliance, engineering, and advisory work; combined they represented about 30% of 2025 service bookings.

Science Group primarily serves businesses and institutions – corporate R&D departments, CROs, and government agencies – with subscription and project revenue; research institution clients and academic partnerships form a smaller, strategic portion of revenue.

Corporate R&D teams, especially in pharma and biotech, are most important by contract size and repeat spend; Science Group's agile science-first hardware and software integration won CTOs and Product Heads, contributing to a ~15% year-on-year market-share gain versus legacy consultancies in early 2026. See the firm's context in this company profile: History and Background of Science Group Company

North America and Europe are the primary Science Group target market because they account for more than 80% of group revenue and host the largest clusters of pharmaceutical and biotech customers, research institution clients, and corporate R&D departments.

Defense and agricultural technology sectors are meaningful secondary markets after the TP Group integration; academic and university clients and long-tail biotech startups form steady recurring demand through subscriptions and consulting.

Science Group core customers center on pharmaceutical and biotech customers and clinical researchers; the medical and regulatory divisions deliver the highest revenue per client and lowest churn, underpinned by non-discretionary spend in healthcare and compliance.

Fastest growth areas include defense services post-TP Group deal, agricultural tech regulatory work via TSG Consulting, industrial digital transformation projects, and the DAB+ radio transition in Frontier Smart Technologies as European mandates roll through 2026. See a market perspective in Growth Outlook of Science Group Company

Science Group target customers expand as the company acquires niche technical consultancies and integrates their offerings into existing sales motions, bringing new research institution clients, pharmaceutical and biotech customers, and government accounts. Cross-selling science-led services into corporate R&D departments and academic and university clients widened the addressable market; recent deals added footholds in defense and environmental sectors, increasing customer count by a reported ~12 percent in the latest fiscal cycle.

Retention hinges on embedding consultants in multi-year pharmaceutical and biotech R&D programs and recurring mandates from clinical researchers and CRO partners; repeat business constitutes a significant share of revenue. Investment in client-specific technical platforms and subscription models for libraries and institutions reduces churn, and the strong balance sheet supports continuity of service during downturns.

Science Group core customers show high loyalty because consultants work across multi-year projects, creating repeat demand from academic researchers, corporate R&D teams, and pharmaceutical procurement officers. Ecosystem stickiness is reinforced by tailored offerings for university libraries and faculty and by partnerships with contract research organizations (CROs), which drive renewals and deeper engagements.

The primary lever is high-value, science-led mandates that are resilient to macro volatility: focusing on core customers – Who are the core customers of Science Group – such as pharmaceutical and biotech customers, research institution clients, and corporate R&D departments. Management projects adjusted operating margins above 18 percent for 2025/2026, supported by a robust balance sheet and targeted acquisitions that add new customer segments with low integration risk. See Ownership and Control of Science Group Company for context on strategic ownership and M&A direction.